MV 130Alternative Names: Bactek; MV-130
Latest Information Update: 18 Feb 2016
At a glance
- Originator Inmunotek
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Bacterial infections
Most Recent Events
- 18 Feb 2016 MV 130 is still in phase III trial for Bacterial infections (Prevention) in Spain (Sublingual) (NCT01842360)
- 13 Dec 2012 Phase-III clinical trials in Bacterial infections (Prevention) in Spain (Sublingual)